| Patient | Benny Leonard |
|---|---|
| Date of birth | 1976-04-07 |
| Identifiers | MRN HR-BX008-SYN; SSN (made up) 000-08-4106 |
| Document date | 2026-08-25 |
| Author | Miriam Okafor-Rosenthal, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Fifteen-week review: blood pressure on the new medicines, kidney function and the sick visit. [S]
Mr. Leonard returns four weeks after the preventive visit, when losartan-hydrochlorothiazide was replaced by losartan 100 mg and amlodipine 5 mg after an episode of volume depletion in the July heat. He has had no lightheadedness since, and he drinks water between bouts and carries the sick-day card. He has refereed full cards every week without chest tightness or breathlessness, including two hot nights. His home readings over the past week averaged 122/76 mmHg. He has slight ankle puffiness at the end of a fight night that is gone by morning. His HIV and hepatitis C tests were negative and the hepatitis B panel showed no immunity; his stool test for colon cancer was negative. He says the money worry is less now that he is working steadily. [S]
| Element | Detail |
|---|---|
| Home blood pressure | Average 122/76 mmHg over seven days |
| Kidney function | Creatinine 1.02 mg/dL, potassium 4.4 mmol/L, four weeks after the change |
| Screening | HIV and hepatitis C negative; hepatitis B not immune; FIT negative |
| System | Result | Finding |
|---|---|---|
| Cardiovascular | Positive | Slight ankle puffiness at the end of fight nights; no chest tightness, palpitations or fainting |
| Constitutional | Negative | No lightheadedness or tiredness |
| Respiratory | Negative | No breathlessness at work |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Losartan 50 mg with hydrochlorothiazide 12.5 mg, one tablet each morning | One tablet each morning | Oral route | 2026-05-12 to 2026-06-30 | completed | S |
| Losartan 100 mg with hydrochlorothiazide 25 mg, one tablet each morning | One tablet each morning; held from the sick visit; stopped at the preventive visit | Oral route | 2026-06-30 to 2026-07-28 | stopped | S |
| Atorvastatin 40 mg tablet, one each evening | One tablet each evening | Oral route | 2026-05-26 | active | S |
| Losartan 100 mg tablet, one each morning | One tablet each morning; hold on sick days | Oral route | 2026-07-28 | active | S |
| Amlodipine 5 mg tablet, one each morning | One tablet each morning | Oral route | 2026-07-28 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-08-25 | Body height | 165 | cm | S |
| 2026-08-25 | Body weight | 73.4 | kg | S |
| 2026-08-25 | Body mass index (BMI) [Ratio] | 27 | kg/m2 | S |
| 2026-08-25 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-08-25 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-08-25 | Heart rate | 68 | /min | S |
| 2026-08-25 | Respiratory rate | 14 | /min | S |
| 2026-08-25 | Body temperature | 36.6 | Cel | S |
| 2026-08-25 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-08-25 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-146 mmol/L | Normal | S |
| 2026-08-25 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.3 mmol/L | Normal | S |
| 2026-08-25 | Urea nitrogen [Mass/volume] in Serum or Plasma | 15 | mg/dL | 7-25 mg/dL | Normal | S |
| 2026-08-25 | Creatinine [Mass/volume] in Serum or Plasma | 1.02 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 2026-08-25 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 88 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-08-25 | Glucose [Mass/volume] in Serum or Plasma | 93 | mg/dL | 65-99 mg/dL | Normal | S |
Vital signs recorded on 2026-08-25; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 124/78 mmHg, pulse 68; weight 73.4 kg; no orthostatic fall |
| Cardiovascular | Regular rhythm; fourth heart sound softer; no murmur; trace ankle edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Breathlessness and tightness across the chest on exertion for about two months, late in long nights of refereeing in hot arenas, easing within a few minutes of rest; never at rest; no fainting, palpitations, orthopnea or ankle swelling; cause under evaluation with a cardiology consultation | resolved | confirmed | R06.09 | S — Synthetic presenting problem anchored to his documented work as a referee; superseded at the consultation when stress testing showed no ischemia and the symptom was attributed to hypertensive heart disease. |
| Stage 2 hypertension found at a yearly fitness examination for his referee's license (164/100 and 160/98 mmHg), with left ventricular hypertrophy by voltage on the ECG; untreated; home readings to follow | resolved | confirmed | I10 | S — Synthetic diagnosis at intake; reclassified as hypertensive heart disease after the echocardiogram at the consultation. |
| Hypertensive heart disease without heart failure: concentric left ventricular hypertrophy (septum 13 mm, mass index 118 g/m2) with normal ejection fraction, grade 1 diastolic dysfunction, a mildly enlarged left atrium and an exaggerated blood pressure rise on exercise; no features of hypertrophic cardiomyopathy | active | confirmed | I11.9 | S — Synthetic diagnosis made at the cardiology consultation; not a claim about his real heart. |
| Coronary atherosclerosis found by coronary calcium scoring (Agatston score 186, about the 80th percentile for his age and sex), without angina and with no inducible ischemia on exercise stress echocardiography | active | confirmed | I25.10 | S — Synthetic diagnosis made at the cardiology consultation; not a retrospective diagnosis of the cause of his death, which is disputed. |
| Hypercholesterolemia: LDL 160 mg/dL, HDL 44 mg/dL, lipoprotein(a) not raised; no diabetes | active | confirmed | E78.00 | S — Synthetic diagnosis at intake. |
| Volume depletion after refereeing a long card in a heat wave while taking losartan 100 mg with hydrochlorothiazide 25 mg: lightheaded on standing, with an orthostatic fall in blood pressure, a prerenal rise in creatinine to 1.44 mg/dL and potassium 3.3 mmol/L; no fainting, chest pain or arrhythmia | resolved | confirmed | E86.0 | S — Synthetic acute problem from the thiazide in summer heat; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Clinic blood pressure, average of two seated readings | Every visit | Completed today | 124/78 mmHg |
| Self-management | Home blood pressure monitoring (validated upper-arm cuff), readings sent weekly | Every day during titration; then a week before each visit | Completed today | Seven-day average 122/76 mmHg: at goal |
| Laboratory | Basic metabolic panel (sodium, potassium, creatinine, eGFR) | Two to four weeks after starting or changing an ARB or diuretic; then every six months | Deferred | The panel ordered two weeks after the dose increase at the seven-week visit was not drawn: he was refereeing four nights that week, and no reminder call was made. The next check was at the sick visit three weeks after the increase, during volume depletion in a heat wave (creatinine 1.44 mg/dL, potassium 3.3 mmol/L), which recovered within a week. An earlier check would probably have been normal and would not have prevented the heat-related episode, but a fall in potassium on the higher thiazide dose could have been found sooner. Corrective action: a standing laboratory order with a reminder call for every check after a medication change |
| Laboratory | Basic metabolic panel (sodium, potassium, creatinine, eGFR), after the change to losartan and amlodipine | Two to four weeks after a change | Completed today | Sodium 140, potassium 4.4 mmol/L, creatinine 1.02 mg/dL, eGFR 88 |
| Laboratory | Lipid panel | Four to twelve weeks after starting a statin; then yearly | Up to date | LDL 66 mg/dL at nine weeks (preventive visit); next in a year |
| Examination | Fundoscopic examination | Yearly | Up to date | Mild arteriolar narrowing at the preventive visit |
| Examination | Symptoms: exertional chest discomfort, breathlessness, palpitations, fainting | Every visit | Completed today | None at full cards, including hot nights |
| Imaging | Echocardiogram | At diagnosis of stage 2 hypertension or suspected hypertrophy; repeat in six to twelve months to judge regression | Up to date | Repeat due six to twelve months after the first |
| Examination | Weight, BMI and physical activity | Every visit | Completed today | 73.4 kg, BMI 27.0 |
| Medication safety | Adherence and side effects (cough, edema, muscle aches, lightheadedness) | Every visit | Completed today | Trace ankle edema on amlodipine; no lightheadedness or muscle aches |
| Self-management | Sick-day rules | When starting an ARB or diuretic | Completed today | Carries the wallet card; knows to skip losartan on sick or very hot days without drinking |
| Self-management | Return to work: refereeing, heat and hydration, warning symptoms, defibrillator at the venue | Before return to full exertion; then every visit | Completed today | Full cards weekly with water between bouts; the venue has a defibrillator at ringside |
Goal progress:
Immunizations given today: Hepatitis B vaccine (HepB-CpG), dose 1 of 2, after a screening panel showed no immunity [S]
Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia (2026); Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 6: Hypertension (2015); CMID: Clinical Monitoring Intelligence Database, hypertension, hyperlipidemia and ischemic heart disease monographs (2026)
Follow-up: First hepatitis B vaccine dose today. Twenty-four-week review at the end of October with the second hepatitis B and zoster doses and the influenza vaccine. Next scheduled visit 2026-10-27: twenty-four-week review: blood pressure control, symptoms at work, mood and worry, aspirin, and the plan ahead. [S]